Skip to main content

3 Result(s)

within Cédric Mercier Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases

    5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers. 5-FU-related toxicities usually include haematological, digestive and cutaneous ...

    Pierre-Yves Cordier, André Nau, Joseph Ciccolini… in Cancer Chemotherapy and Pharmacology (2011)

  2. No Access

    Article

    Integrating pharmacogenetics into gemcitabine dosing—time for a change?

    A number of biomarkers that predict clinical outcome in response to gemcitabine treatment have been identified. These markers could be used in the clinic to personalize treatment, thereby improving efficacy an...

    Joseph Ciccolini, Cédric Mercier, Laetitia Dahan… in Nature Reviews Clinical Oncology (2011)

  3. No Access

    Article

    DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

    Fluoropyrimidine drugs are widely used in head and neck cancer (HNC). DPD deficiency is a pharmacogenetics syndrome associated with severe/lethal toxicities upon 5-FU or capecitabine intake. We have developed ...

    Chen Guang Yang, Joseph Ciccolini, Aurore Blesius… in Cancer Chemotherapy and Pharmacology (2011)